Pages that link to "Q37468412"
The following pages link to Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus (Q37468412):
Displaying 32 items.
- Cardiovascular safety of anti-diabetic drugs (Q26741082) (← links)
- Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease (Q28069065) (← links)
- Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents (Q28074843) (← links)
- Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review (Q28079134) (← links)
- Adverse effects and safety of SGLT-2 inhibitors (Q28082331) (← links)
- Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes (Q33837017) (← links)
- De novo expression of sodium-glucose cotransporter SGLT2 in Bowman's capsule coincides with replacement of parietal epithelial cell layer with proximal tubule-like epithelium (Q33983846) (← links)
- Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention (Q34201551) (← links)
- The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system (Q34503796) (← links)
- Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial. (Q35558413) (← links)
- Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes (Q35780861) (← links)
- Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview. (Q35831426) (← links)
- Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin (Q36169413) (← links)
- Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus (Q36804248) (← links)
- Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study (Q37080615) (← links)
- Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement (Q37588847) (← links)
- Is it time to think about the sodium glucose co-transporter 2 sympathetically? (Q38586588) (← links)
- Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes (Q38783203) (← links)
- Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus (Q38906041) (← links)
- Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus (Q39006105) (← links)
- Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C. (Q39865389) (← links)
- A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes (Q47766606) (← links)
- Crosstalk of Hyperglycemia and Dyslipidemia in Diabetic Kidney Disease (Q49982517) (← links)
- Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice. (Q53322628) (← links)
- Phloridzin, an Apple Polyphenol, Exerted Unfavorable Effects on Bone and Muscle in an Experimental Model of Type 2 Diabetes in Rats (Q58600349) (← links)
- Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Presenting with Acute Pancreatitis (Q58797007) (← links)
- Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control (Q64294550) (← links)
- Localization of Glucose Transporter 10 to Hair Cells' Cuticular Plate in the Mouse Inner Ear. (Q64912957) (← links)
- Risks vs Benefits for SGLT2 Inhibitor Medications. (Q64928186) (← links)
- The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data (Q89159569) (← links)
- Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis (Q91716515) (← links)
- A UPLC/DAD method for simultaneous determination of empagliflozin and three related substances in spiked human plasma (Q92438019) (← links)